Adage Capital Partners Gp, L.L.C. Regeneron Pharmaceuticals, Inc. Transaction History

Adage Capital Partners Gp, L.L.C.

$54.6 Billion
Q3 2024

A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 169,639 shares of REGN stock, worth $119 Million. This represents 0.33% of its overall portfolio holdings.

Number of Shares

169,639

Previous 162,499 4.39%

Holding current value

$119 Million

Previous $171 Million 4.41%

% of portfolio

0.33%

Previous 0.33%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$1024.09 - $1201.76 $7.31 Million - $8.58 Million	7,140 Added 4.39%	169,639 $178 Million
Q2 2024 Aug 14, 2024	BUY	$883.2 - $1071.19 $26.8 Million - $32.5 Million	30,361 Added 22.98%	162,499 $171 Million
Q1 2024 May 15, 2024	SELL	$902.69 - $993.35 $3.17 Million - $3.49 Million	-3,511 Reduced 2.59%	132,138 $127 Million
Q4 2023 Feb 14, 2024	BUY	$775.18 - $881.7 $31.7 Million - $36.1 Million	40,900 Added 43.17%	135,649 $119 Million
Q3 2023 Nov 14, 2023	SELL	$692.45 - $844.37 $30 Million - $36.6 Million	-43,300 Reduced 31.37%	94,749 $78 Million
Q2 2023 Aug 14, 2023	SELL	$700.03 - $830.35 $24.6 Million - $29.2 Million	-35,200 Reduced 20.32%	138,049 $99.2 Million
Q1 2023 May 15, 2023	BUY	$680.49 - $826.97 $68.7 Million - $83.5 Million	100,927 Added 139.55%	173,249 $142 Million
Q4 2022 Feb 14, 2023	BUY	$705.89 - $766.39 $7.11 Million - $7.72 Million	10,073 Added 16.18%	72,322 $52.2 Million
Q3 2022 Nov 14, 2022	BUY	$573.97 - $724.32 $35.7 Million - $45.1 Million	62,249 New	62,249 $42.9 Million
Q2 2022 Aug 15, 2022	SELL	$548.35 - $738.84 $51.8 Million - $69.8 Million	-94,449 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$595.12 - $698.43 $714,144 - $838,115	-1,200 Reduced 1.25%	94,449 $66 Million
Q4 2021 Feb 14, 2022	BUY	$543.48 - $670.97 $89,674 - $110,710	165 Added 0.17%	95,649 $60.4 Million
Q3 2021 Nov 15, 2021	SELL	$574.03 - $680.96 $701,464 - $832,133	-1,222 Reduced 1.26%	95,484 $57.8 Million
Q2 2021 Aug 16, 2021	BUY	$472.8 - $558.54 $22.8 Million - $27 Million	48,300 Added 99.78%	96,706 $54 Million
Q1 2021 May 17, 2021	SELL	$446.73 - $548.2 $23.3 Million - $28.6 Million	-52,200 Reduced 51.89%	48,406 $22.9 Million
Q4 2020 Feb 16, 2021	SELL	$478.3 - $607.98 $540,479 - $687,017	-1,130 Reduced 1.11%	100,606 $48.6 Million
Q3 2020 Nov 16, 2020	SELL	$544.75 - $658.21 $26.8 Million - $32.4 Million	-49,150 Reduced 32.57%	101,736 $57 Million
Q2 2020 Aug 14, 2020	BUY	$493.32 - $643.92 $41.8 Million - $54.6 Million	84,808 Added 128.35%	150,886 $94.1 Million
Q1 2020 May 15, 2020	BUY	$336.18 - $494.43 $22.2 Million - $32.7 Million	66,078 New	66,078 $32.3 Million
Q1 2019 May 15, 2019	SELL	$372.08 - $439.57 $13.8 Million - $16.3 Million	-37,021 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$335.82 - $403.04 $17.5 Million - $21 Million	-52,200 Reduced 58.51%	37,021 $13.8 Million
Q3 2018 Nov 14, 2018	BUY	$351.14 - $408.51 $31.3 Million - $36.4 Million	89,221 New	89,221 $36 Million
Q4 2017 Feb 14, 2018	SELL	$358.63 - $469.95 $4.27 Million - $5.6 Million	-11,910 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$431.38 - $504.0 $5.14 Million - $6 Million	11,910	11,910 $5.33 Million

Others Institutions Holding REGN

# of Institutions

1,534

Shares Held

83.6M

Call Options Held

1.22M

Put Options Held

1.51M

View Full List

About REGENERON PHARMACEUTICALS, INC.

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $75.2B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

More about REGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.

Account

Adage Capital Partners Gp, L.L.C. Regeneron Pharmaceuticals, Inc. Transaction History